TrialGynecologic oncology2014

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Susana M Campos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.